CD40 ligand adjuvant for respiratory syncytial virus

US8354115B2 · kind B2 · utility

Assignee

• THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION · US

Inventors

• Ralph A. Tripp · Watkinsville, US
• Larry J. Anderson · Blue Springs, US
• Michael Brown · Adelaide, AU

Key dates

• Filing date: Apr 4, 2008
• Grant date: Jan 15, 2013
• Expiry date: Jun 22, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2760/18634
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides methods and adjuvants for enhancing an immune response to RSV in a host, wherein the methods and adjuvants comprise a source of a CD40 binding protein. Preferably, the CD40 binding protein is CD40L and the source is a vector comprising a promoter operatively linked to a CD40L coding region. The enhanced immune response produced by the adjuvants and methods of the current invention includes both increased expression of Th1 cytokines and increased production of antibody.